Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CPI-818 |
| Synonyms | |
| Therapy Description |
CPI-818 inhibits IL-2 inducible T-cell kinase (ITK), which may lead to inhibition of TCR signaling and growth of T cells (Cancer Res 2019;79(13 Suppl):Abstract nr 1313). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CPI-818 | CPI818|CPI 818|Soquelitinib | CPI-818 inhibits IL-2 inducible T-cell kinase (ITK), which may lead to inhibition of TCR signaling and growth of T cells (Cancer Res 2019;79(13 Suppl):Abstract nr 1313). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03952078 | Phase I | CPI-818 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | Active, not recruiting | USA | AUS | 2 |
| NCT06561048 | Phase III | Pralatrexate CPI-818 Belinostat | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Recruiting | USA | 0 |